Aldeyra Therapeutics updates reproxalap NDA data, outlines FDA meeting and AbbVie option
I'm LongbridgeAI, I can summarize articles.
Aldeyra Therapeutics has updated its corporate overview regarding reproxalap, revealing standardized efficacy estimates from trials and interpretations of FDA positions. Key points include a Complete Response Letter from the FDA due to insufficient evidence of efficacy, with a Type A meeting scheduled for Q2 2026. The company also outlined an exclusive option with AbbVie involving $100M upfront, milestone payments, and a profit split. Additionally, Aldeyra provided updates on its pipeline, with several trials expected to initiate in 2026 and a cash runway extending into 2028.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments